Twelve new companies joined Wuxi International Life Science Innovation Campus (I•Campus) at the 3rd CIIE in Shanghai. [Photo provided to chinadaily.com.cn]
Wuxi International Life Science Innovation Campus (I•Campus), an innovation incubation platform co-built by Wuxi municipal government in Jiangsu province, Wuxi Hi-tech District and AstraZeneca, signed up 12 new innovative companies from home and abroad, secured two innovative partnerships with resident companies, and unveiled several significant inaugurations and signing ceremonies at the 3rd China International Import Expo.
Government officials, including Hui Jianlin, vice-governor of Jiangsu provincial, Helena Sangeland, Swedish ambassador to China, Jiang Min, deputy mayor of Wuxi city, attended the ceremonies, together with executives from AstraZeneca, such as Leon Wang, executive vice-president of AstraZeneca and president of its China arm, and Michael Lai, general manager of AstraZeneca China, and representatives from signing companies.
Supported by Wuxi municipal government and Wuxi Hi-tech District, I•Campus held its opening ceremony in September 2019 and began full business operation in April 2020. Despite the pandemic, I•Campus has been able to maintain close ties with domestic and foreign partners, through which it managed to introduce innovative forces into China and empower the growth of its resident companies.
During the ongoing CIIE, Wuxi government, AstraZeneca, Tigermed, CICC and other companies jointly released the plan for "Wuxi International Health Investment and Innovation Summit". I•Campus itself entered strategic cooperation with BioVenture Hub from Sweden on medical innovation, facilitating further industrial integration and development of healthcare innovation.
Wang from AstraZeneca said, "The CIIE provides an excellent platform for empowering bilateral innovation exchange and cooperation between domestic and foreign partners.
"We are seeking more partners to build a global healthcare innovation ecosystem characterized by openness, collaboration, and mutual benefits, seeking to grow our own business while contributing to the strengthening of China's healthcare innovation capability and benefiting patients in China and beyond."
